C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
The C-C Chemokine Receptor Type 5 pipeline drugs market research report outlays comprehensive information on the C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also reviews key players involved in C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics development with respective active and dormant or discontinued projects.
CHEMR13 Pipeline Drugs Market Segmentation by Therapy Areas
The key therapy areas in the CHEMR13 pipeline drugs market are infectious disease, central nervous system, oncology, respiratory, gastrointestinal, and toxicology.
CHEMR13 Pipeline Drugs Market Analysis, by Therapy Areas, 2022 (%)
For more CHEMR13 pipeline drugs therapy area insights, download a free report sample
CHEMR13 Pipeline Drugs Market Segmentation by Key Mechanism of Actions
The key mechanism of actions in the CHEMR13 pipeline drugs market are C-C Chemokine Receptor Type 5 Antagonist and C-C Chemokine Receptor Type 5 Inhibitor.
CHEMR13 Pipeline Drugs Market Analysis, by Mechanism of Actions, 2022 (%)
For more CHEMR13 pipeline drugs mechanism of actions insights, download a free report sample
CHEMR13 Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the CHEMR13 pipeline drugs market are intravenous, oral, subcutaneous, vaginal, intraperitoneal, rectal, and parenteral.
CHEMR13 Pipeline Drugs Market Analysis, by Routes of Administration, 2022 (%)
For more CHEMR13 pipeline drugs routes of administration insights, download a free report sample
CHEMR13 Pipeline Drugs Market Segmentation by Molecule Types
The key molecule types in the CHEMR13 pipeline drugs market are small molecule, monoclonal antibody, synthetic peptide, antisense RNAi oligonucleotide, and gene-modified cell therapy.
CHEMR13 Pipeline Drugs Market Analysis, by Molecule Types, 2022 (%)
For more CHEMR13 pipeline drugs molecule type insights, download a free report sample
Competitive Landscape
Some of the leading companies in the CHEMR13 pipeline drugs market are American Gene Technologies International Inc, Aphios Corp, Bristol-Myers Squibb Co, Creative Bio-Peptides Inc, Cytodyn Inc, Forest Hills Partners Hong Kong Ltd, GSK plc, Merck & Co Inc, Novartis AG, and Orion Biotechnology Canada Ltd.
CHEMR13 Pipeline Drugs Market Analysis, by Companies, 2022 (%)
To know more about the CHEMR13 pipeline drugs companies, download a free report sample
CHEMR13 Pipeline Drugs Market Report Overview
| Key Therapy Areas | Infectious Disease, Central Nervous System, Oncology, Respiratory, Gastrointestinal, and Toxicology |
| Key Mechanism of Actions | C-C Chemokine Receptor Type 5 Antagonist and C-C Chemokine Receptor Type 5 Inhibitor |
| Key Routes of Administration | Intravenous, Oral, Subcutaneous, Vaginal, Intraperitoneal, Rectal, and Parenteral |
| Key Molecule Types | Small Molecule, Monoclonal Antibody, Synthetic Peptide, Antisense RNAi Oligonucleotide, and Gene-Modified Cell Therapy |
| Leading Companies | American Gene Technologies International Inc, Aphios Corp, Bristol-Myers Squibb Co, Creative Bio-Peptides Inc, Cytodyn Inc, Forest Hills Partners Hong Kong Ltd, GSK plc, Merck & Co Inc, Novartis AG, and Orion Biotechnology Canada Ltd |
Segments Covered in the Report
CHEMR13 Pipeline Drugs Market Therapy Areas Outlook
- Infectious Disease
- Central Nervous System
- Oncology
- Respiratory
- Gastrointestinal
- Toxicology
CHEMR13 Pipeline Drugs Market Mechanism of Actions Outlook
- C-C Chemokine Receptor Type 5 Antagonist
- C-C Chemokine Receptor Type 5 Inhibitor
CHEMR13 Pipeline Drugs Market Routes of Administration Outlook
- Intravenous
- Oral
- Subcutaneous
- Vaginal
- Intraperitoneal
- Rectal
- Parenteral
CHEMR13 Pipeline Drugs Market Molecule Types Outlook
- Small Molecule
- Monoclonal Antibody
- Synthetic Peptide
- Antisense RNAi Oligonucleotide
- Gene-Modified Cell Therapy
Scope
This report provides:
- A snapshot of the global therapeutic landscape for C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5).
- Reviews of C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which includes product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
- Reviews of key players involved in C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics and enlists all their major and minor projects.
- Assessment of C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA), and molecule type.
- Summaries of all the dormant and discontinued pipeline projects.
- Reviews of the latest news and deals related to C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics.
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
- Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
- Identify and understand the targeted therapy areas and indications for C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5). Identify the use of drugs for target identification and drug repurposing.
- Identify potential new clients or partners in the target demographic.
- Develop strategic initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics.
- Devise corrective measures for pipeline projects by understanding C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) development landscape.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Aphios Corp
Bristol-Myers Squibb Co
Creative Bio-Peptides Inc
Cytodyn Inc
Forest Hills Partners Hong Kong Ltd
GSK plc
Merck & Co Inc
Novartis AG
Orion Biotechnology Canada Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key therapy areas of the CHEMR13 pipeline drugs market?
The key therapy areas in the CHEMR13 pipeline drugs market are infectious disease, central nervous system, oncology, respiratory, gastrointestinal, and toxicology.
-
What are the key mechanism of actions in the CHEMR13 pipeline drugs market?
The key mechanism of actions in the CHEMR13 pipeline drugs market are C-C Chemokine Receptor Type 5 Antagonist and C-C Chemokine Receptor Type 5 Inhibitor.
-
What are the key routes of administration in the CHEMR13 pipeline drugs market?
The key routes of administration in the CHEMR13 pipeline drugs market are intravenous, oral, subcutaneous, vaginal, intraperitoneal, rectal, and parenteral.
-
What are the key molecule types in the CHEMR13 pipeline drugs market?
The key molecule types in the CHEMR13 pipeline drugs market are small molecule, monoclonal antibody, synthetic peptide, antisense RNAi oligonucleotide, and gene-modified cell therapy.
-
Which are the key companies in the CHEMR13 pipeline drugs market?
The key companies in the CHEMR13 pipeline drugs market are American Gene Technologies International Inc, Aphios Corp, Bristol-Myers Squibb Co, Creative Bio-Peptides Inc, Cytodyn Inc, Forest Hills Partners Hong Kong Ltd, GSK plc, Merck & Co Inc, Novartis AG, and Orion Biotechnology Canada Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Sample Report
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
Related reports
View more Other Diseases reports